WEZENLA 45 mg, solution for injection in a pre-filled pen pen, 0.5 ml
Active ingredients: USTÉKINUMAB
Commercialized according to BDPMDispensing in France: Prescription only
Solution for injectionpen, 0.5 mlsous-cutanée
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- WEZENLA 45 mg, solution injectable en stylo prérempli
- Pharmaceutical form
- solution injectable
- Route of administration
- sous-cutanée
- Presentation description
- 1 stylo prérempli en verre de 0,5 ml
- Marketing authorisation holder
- AMGEN TECHNOLOGY (IRELAND)
- Reimbursement according to BDPM
- 65%
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 24 Jun 2025
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Prescribed by specialists only
- Enhanced ANSM monitoring
- Yes
BDPM identifiers
CIS
64226115CIP73031066CIP133400930310663Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| USTÉKINUMABsolution | 45 mg · un stylo prérempli de 0,5 mL de solution | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.